PROGRAM PRIORITIZATION
Whether you are a bio-pharmaceutical firm, a medical device firm, a drug discovery tool technology or a diagnostic firm, developing products for life science markets requires vast resources. Scientia works with clients to assess technologies and markets. We use both primary and secondary research to prioritize development of products. We also work with executive teams to create strategies that identify product from both internal research as well as academia. Scientia has expertise in developing strategies for successful life science firms.To find out more about Scientia’s work in this capability area, please contact us.
Molecular Imaging in Drug Development
An industry commentary by Scientia Advisors, LLC
Molecular imaging promises to be a very interesting growth area in drug discovery in both preclinical and clinical markets. There is considerable enthusiasm in the pre-clinical market to expand its use and a more cautious approach in the clinical market. In either market, the drivers of growth will be the adoption of functional imaging technologies to gain access to higher quality in vivo data. The size of the opportunity for suppliers of molecular imaging products and services is huge. If the more than $12B spent annually by pharmaceutical companies for preclinical and Phase I drug discovery and the approximately $2.9B1 on translation research at academic and research institutions are combined, suppliers are competing for a share of nearly $15B in spending.
An industry commentary by Scientia Advisors, LLC
Molecular imaging promises to be a very interesting growth area in drug discovery in both preclinical and clinical markets. There is considerable enthusiasm in the pre-clinical market to expand its use and a more cautious approach in the clinical market. In either market, the drivers of growth will be the adoption of functional imaging technologies to gain access to higher quality in vivo data. The size of the opportunity for suppliers of molecular imaging products and services is huge. If the more than $12B spent annually by pharmaceutical companies for preclinical and Phase I drug discovery and the approximately $2.9B1 on translation research at academic and research institutions are combined, suppliers are competing for a share of nearly $15B in spending.
